Skip to main content
OpenTrials
Completed

NCT Number: NCT00572494

AMS INSIGHT 1 Study - Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment

Prospective, multicenter, randomized clinical trial, Follow-up at 1-, 6- and 12 months

This clinical investigation is first of all designed to demonstrate the safety and effectiveness of the MAGIC EXPLORER stent system. The primary objectives of the study are to evaluate the safety and 6-month patency of the bioabsorbable MAGIC EXPLORER stent in patients with stenotic or occlusive atherosclerotic disease of the infrapopliteal arteries. Secondary endpoints are the procedural success, patency at all follow-ups, late lumen loss and limb-salvage rate. Peri-procedural complications (within 24 hours) will be evaluated. Furthermore, data of the balloon catheter PLEON EXPLORER will be collected to demonstrate its effectiveness and safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Peripheral Artery Disease Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Peripheral Arterial Disease Peripheral Vascular Diseases Vascular Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Medizinische Universität Graz, Graz, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Stenotic (> 50%) or occlusive atherosclerotic disease of the infrapopliteal arteries
  • Length of lesion < 20mm (less than one stent length)
  • Reference vessel diameter should be 3.0-3.5 mm
  • A maximum of two lesions in one infrapopliteal vessel treated within the study, or in two vessels of two different legs. (PTA treatment of other infrapopliteal lesions in non-study vessels is allowed outside the study).
  • Symptomatic critical limb ischemia (Rutherford 4, 5)
  • The patient must be ≥ 50 years.
  • Life-expectancy of more than 6 months
  • The subject or legal guardian has been informed of the nature of the study; agrees to its provisions and has signed informed consent
  • The patient must be available for the appropriate follow-up times for the duration of the study
  • The patient is capable to follow all study requirements.

Exclusion criteria

  • Patient refusing treatment
  • The reference segment diameter is not suitable for available stent design
  • Length of lesion requires more than one stent implantation
  • Previously implanted stent(s) or PTA at the same lesion site
  • Lesion lies within or adjacent to an aneurysm
  • Inflow-limiting arterial lesions left untreated
  • The patient has a known allergy to heparin, Aspirin or other anticoagulant/antiplatelet therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
  • The patient takes Phenprocoumon (Marcumar).
  • The patient has a history of prior life-threatening contrast media reaction.
  • The patient is currently enrolled in another investigational device or drug trial.
  • The patient is currently breast-feeding, pregnant or intends to become pregnant.
  • The patient is mentally ill or retarded.
  • The patient is liable for military or civilian service.

Treatment and study plan

MAGIC EXPLORER (Biotronik AG)

Device

The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.

PLEON EXPLORER (Biotronik AG)

Device

The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.

Primary outcomes

  1. Efficacy : patency of the AMS, defined as the absence of a hemodynamically significant restenosis (> 50%)

    Time frame: 6 month

  2. Safety: Complications at 1 month post-procedure (major amputations or any cause of death)

    Time frame: 1 month

Secondary outcomes

  1. Immediate angiographic procedural success, defined as maximal 30% residual stenosis on visual assessment of the planned treatment area.

    Time frame: procedure

  2. Patency at follow-up visits determined with Color Flow Doppler Ultrasound (CFDU)

    Time frame: 1 & 6 months

  3. Late lumen loss at 6 months.

    Time frame: 6 months

  4. Limb-salvage rate at follow-up visits, defined as lack of major amputation.

    Time frame: 1 & 6 months

Sponsors and collaborators

Lead sponsor

Flanders Medical Research Program

Network

Collaborators

  • Biotronik SE & Co. KG

Registry information

Official study title

Bioabsorbable Metal Stent Investigation in Chronic Limb Ischemia Treatment

Acronym: AMS-INSIGHT1

Important dates

Study start
2005
Study completion
2007
First posted
Dec 13, 2007
Registry last updated
Feb 8, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.